Serum Institute has reportedly begun at-risk production of its second Covid-19 vaccine Covavax.The SII is manufacturing US biotechnology company Novavax’s protein-based Covid-19 vaccine, NVX-CoV2373, under the brand name Covovax.Further, Dr Paul added that the World Health Organisation (WHO) has not given any recommendation yet to cover children for the vaccine trial."WHO hasn't given any recommendation yet to cover pediatric population in general as any illness in the pediatric population is very very mild.
If we go with a paradigm of deaths as a public health objective, it's at a lower priority," he added.On the supply of Covid-19 vaccines to states, Dr Paul said, "To say that the supply has closed isn't true.